Cantor Fitzgerald Predicts Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Rezolute in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($0.97) for the year. The consensus estimate for Rezolute's current full-year earnings is ($0.99) per share.

A number of other analysts also recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Rezolute in a report on Friday, November 8th. Wedbush reiterated an "outperform" rating and issued a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Rezolute presently has an average rating of "Buy" and a consensus price target of $24.13.

Rezolute Trading Up 3.7 %

Shares of RZLT traded up $0.18 during mid-day trading on Thursday, hitting $4.99. The company's stock had a trading volume of 4,356,668 shares, compared to its average volume of 674,026. Rezolute has a 1-year low of $0.92 and a 1-year high of $6.19. The firm has a market capitalization of $289.12 million, a P/E ratio of -3.93 and a beta of 1.08. The firm has a 50-day simple moving average of $4.89 and a 200 day simple moving average of $4.85.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.13.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans purchased 9,000 shares of Rezolute stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $4.60 per share, with a total value of $41,400.00. Following the purchase, the chief financial officer now directly owns 140,900 shares in the company, valued at $648,140. This trade represents a 6.82 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.39% of the stock is owned by insiders.

Hedge Funds Weigh In On Rezolute

Several institutional investors have recently added to or reduced their stakes in RZLT. JPMorgan Chase & Co. purchased a new stake in Rezolute in the 3rd quarter valued at about $42,000. MML Investors Services LLC acquired a new stake in shares of Rezolute in the third quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Rezolute in the third quarter valued at approximately $65,000. Virtu Financial LLC increased its position in Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock worth $126,000 after purchasing an additional 9,551 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company's stock worth $145,000 after purchasing an additional 22,660 shares during the period. 82.97% of the stock is currently owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.